TTNPB (Synonyms: Ro 13-7410; Arotinoid acid; AGN191183)

Name: TTNPB
Brand: MedChemExpress
SKU: HY-15682
Rating: 5.0 (5 reviews)

Cat. No.: HY-15682 Purity: 99.85%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

TTNPB is a highly potent RAR agonist. Competitive binding assays using human RARs yield IC₅₀s of α=5.1 nM, β= 4.5 nM, and γ=9.3 nM, respectively.

For research use only. We do not sell to patients.

CAS No. : 71441-28-6

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 5 publication(s) in Google Scholar

Other Forms of TTNPB:

TTNPB (GMP) Get quote
TTNPB (Standard) Get quote

5 Publications Citing Use of MCE TTNPB

Flow Cytometry

In Vivo Efficacy Study

Histological Imaging/Staining

: TTNPB purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 27:e09340. [Abstract]; A) Flow cytometry analysis showing HLA-DR expression after IFN-γ +TTNPB (0.01 nM-100 μM) and IFN-γ +Bexarotene treatment for 48 h. B) Flow cytometry analysis showing CD40 expression after IFN +TTNPB and IFN-γ +Bexarotene treatment for 48 h in mast cells.

: TTNPB purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2024 Nov;45(11):2290-2299.; Schemes of generating Fsp1-Cre:R26R-loxp-tdTomato mice and drug treatment to induce in situ transdifferentiation. Fsp1-Cre mice were crossed with R26Rloxp-tdTomato mice in which the expression of tdTomato is prevented by a loxP-flanked STOP cassette. The F1 mice would have the red fluorescent protein tdTomato expressed specifically in the fibroblasts. CRFVPTM were given once a week for 6 weeks. Immunofluorescence staining of the cryosections of the hearts from Fsp1-Cre:R26R-loxp-tdTomato mice treated with vehicle (b) or CRFVPTM (c) for 6 weeks. C: CHIR99021, 14 mg/kg; R: RepSox, 8.6 mg/kg; F: Forskolin, 61.6 mg/kg; V: VPA, 250 mg/kg; T: TTNPB, 1 mg/kg and M: Rolipram, 2.5 mg/kg; P: Parnate, 2.7 mg/kg, CRFTM by oral gavage and VP by intraperitoneal injection once a week for 6 weeks in mice at about 8 weeks of age.

: TTNPB purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2024 Nov;45(11):2290-2299.; Whole-heart imaging with light-sheet fluorescence microscopy after tissue clearing of the hearts from Fsp1-Cre:R26R-loxp-tdTomato mice treated with vehicle (a) or CRFVPTM (b). (C: CHIR99021, 14 mg/kg; R: RepSox, 8.6 mg/kg; F: Forskolin, 61.6 mg/kg; V: VPA, 250 mg/kg; T: TTNPB, 1 mg/kg and M: Rolipram, 2.5 mg/kg; P: Parnate, 2.7 mg/kg, CRFTM by oral gavage and VP by intraperitoneal injection once a week for 6 weeks in mice at about 8 weeks of age).

: TTNPB purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2024 Nov;45(11):2290-2299.; a Schemes of obtaining PDGFRα-DreER:R26R-rox-tdTomato mice and drug treatment to induce in situ cardiac reprogramming in PDGFRα-DreER:R26R-roxtdTomato mice. PDGFRα-DreER mice were mated with R26R-rox-tdTomato mice in which the expression of tdTomato is prevented by a roxflanked STOP cassette. The expression of tdTomato in fibroblasts was turned on by tamoxifen treatment. CRFVPTM were given once a week for 6 weeks. b Body weigh change of the mice after chemical treatment. Immunofluorescence staining of the cryosections of the hearts from PDGFRα-DreER:R26R-rox-tdTomato mice treated with vehicle (c) or CRFVPTM (d) for 6 weeks. (C: CHIR99021, 14 mg/kg; R: RepSox, 8.6 mg/kg; F: Forskolin, 61.6 mg/kg; V: VPA, 250 mg/kg; T: TTNPB, 1 mg/kg and M: Rolipram, 2.5 mg/kg; P: Parnate, 2.7 mg/kg, CRFTM by oral gavage and VP by intraperitoneal injection once a week for 6 weeks in mice at about 8 weeks of age).

: TTNPB purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2024 Nov;45(11):2290-2299.; Immunofluorescence staining of α-actinin in cryosections of hearts from Fsp1-Cre:R26R-loxp-tdTomato mice treated with 7 C cocktail (CRFVPTM) or cocktails by removing 1 compound from 7 C (7C-X) for 6 weeks in vivo with Fsp1-Cre:R26R-loxp-tdTomato mice. (C: CHIR99021, 14 mg/kg; R: RepSox, 8.6 mg/kg; F: Forskolin, 61.6 mg/kg; V: VPA, 250 mg/kg; T: TTNPB, 1 mg/kg and M: Rolipram, 2.5 mg/kg; P: Parnate, 2.7 mg/kg, CRFTM by oral gavage and VP by intraperitoneal injection once a week for 6 weeks in mice at about 8 weeks of age).

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All RAR/RXR Isoform Specific Products:

View All Isoforms

RXRα RXRβ RXRγ

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

TTNPB is a highly potent RAR agonist. Competitive binding assays using human RARs yield IC₅₀s of α=5.1 nM, β= 4.5 nM, and γ=9.3 nM, respectively.

IC₅₀ & Target

IC50: 5.1 nM (RARα), 4.5 nM (RARβ), 9.3 nM (RARγ)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
F9	ED₅₀	0.08 1 Compound: 2	Ability to displace 3 uM retinoid and [3H]all-trans-retinoic acid in F9 embryonal carcinoma cells using F9 Plasminogen Activator releasing assay Ability to displace 3 uM retinoid and [3H]all-trans-retinoic acid in F9 embryonal carcinoma cells using F9 Plasminogen Activator releasing assay	[PMID: 2738885]
F9	ED₅₀	0.08 1 Compound: 2	Ability to displace 3 uM retinoid and [3H]all-trans-retinoic acid in F9 embryonal carcinoma cells using F9 Plasminogen Activator releasing assay Ability to displace 3 uM retinoid and [3H]all-trans-retinoic acid in F9 embryonal carcinoma cells using F9 Plasminogen Activator releasing assay	[PMID: 2738885]
HEK293	EC₅₀	0.18 1 Compound: TTNPB	Agonist activity at human RARalpha expressed in HEK293 cells by luciferase reporter gene assay Agonist activity at human RARalpha expressed in HEK293 cells by luciferase reporter gene assay	[PMID: 25305688]
HEK293	EC₅₀	0.18 1 Compound: TTNPB	Agonist activity at human RARalpha expressed in HEK293 cells by luciferase reporter gene assay Agonist activity at human RARalpha expressed in HEK293 cells by luciferase reporter gene assay	[PMID: 25305688]
F9	ED₅₀	1.5 1 Compound: 2	Ability to displace [3H]all-trans-retinoic acid from F9 embryonal carcinoma cells, was assessed in a F9 laminin release assay Ability to displace [3H]all-trans-retinoic acid from F9 embryonal carcinoma cells, was assessed in a F9 laminin release assay	[PMID: 2738885]
CV-1	EC₅₀	2 1 Compound: TTNPB	Binding affinity against retinoic Acid gamma receptors co-transfected into CV-1 cells Binding affinity against retinoic Acid gamma receptors co-transfected into CV-1 cells	[PMID: 8308867]
CV-1	EC₅₀	3 1 Compound: TTNPB	Binding affinity against retinoic Acid beta receptors co-transfected into CV-1 cells Binding affinity against retinoic Acid beta receptors co-transfected into CV-1 cells	[PMID: 8308867]
CV-1	EC₅₀	>10 3 Compound: TTNPB	Binding affinity against retinoic Acid X alpha receptors co-transfected into CV-1 cells Binding affinity against retinoic Acid X alpha receptors co-transfected into CV-1 cells	[PMID: 8308867]
HL-60	EC₅₀	>1 3 Compound: 9 (TTNPB)	Induction of transglutaminase (TGase) activity in HL-60 cells Induction of transglutaminase (TGase) activity in HL-60 cells	[PMID: 8784454]
HL-60	EC₅₀	>1 3 Compound: 1	Transglutaminase activity in HL-60 cdm-1 cells Transglutaminase activity in HL-60 cdm-1 cells	[PMID: 7636843]
HL-60	IC₅₀	46 3 Compound: 3	In vitro cytotoxicity against HL60 cells. In vitro cytotoxicity against HL60 cells.	[PMID: 11128648]
CV-1	EC₅₀	30 1 Compound: TTNPB	Binding affinity against retinoic Acid alpha receptors co-transfected into CV-1 cells Binding affinity against retinoic Acid alpha receptors co-transfected into CV-1 cells	[PMID: 8308867]
CV-1	EC₅₀	2 1 Compound: TTNPB	Binding affinity against retinoic Acid gamma receptors co-transfected into CV-1 cells Binding affinity against retinoic Acid gamma receptors co-transfected into CV-1 cells	[PMID: 8308867]
CV-1	EC₅₀	3 1 Compound: TTNPB	Binding affinity against retinoic Acid beta receptors co-transfected into CV-1 cells Binding affinity against retinoic Acid beta receptors co-transfected into CV-1 cells	[PMID: 8308867]
CV-1	EC₅₀	30 1 Compound: TTNPB	Binding affinity against retinoic Acid alpha receptors co-transfected into CV-1 cells Binding affinity against retinoic Acid alpha receptors co-transfected into CV-1 cells	[PMID: 8308867]
CV-1	EC₅₀	> 10000 1 Compound: TTNPB	Binding affinity against retinoic Acid X alpha receptors co-transfected into CV-1 cells Binding affinity against retinoic Acid X alpha receptors co-transfected into CV-1 cells	[PMID: 8308867]
CV-1	EC₅₀	> 10000 1 Compound: TTNPB	Binding affinity against retinoic Acid X beta receptors co-transfected into CV-1 cells Binding affinity against retinoic Acid X beta receptors co-transfected into CV-1 cells	[PMID: 8308867]
CV-1	EC₅₀	> 10000 1 Compound: TTNPB	Binding affinity against retinoic Acid X gamma receptors co-transfected into CV-1 cells Binding affinity against retinoic Acid X gamma receptors co-transfected into CV-1 cells	[PMID: 8308867]
F9	ED₅₀	0.08 1 Compound: 2	Ability to displace 3 uM retinoid and [3H]all-trans-retinoic acid in F9 embryonal carcinoma cells using F9 Plasminogen Activator releasing assay Ability to displace 3 uM retinoid and [3H]all-trans-retinoic acid in F9 embryonal carcinoma cells using F9 Plasminogen Activator releasing assay	[PMID: 2738885]
F9	ED₅₀	1.5 1 Compound: 2	Ability to displace [3H]all-trans-retinoic acid from F9 embryonal carcinoma cells, was assessed in a F9 laminin release assay Ability to displace [3H]all-trans-retinoic acid from F9 embryonal carcinoma cells, was assessed in a F9 laminin release assay	[PMID: 2738885]
HEK293	EC₅₀	0.18 1 Compound: TTNPB	Agonist activity at human RARalpha expressed in HEK293 cells by luciferase reporter gene assay Agonist activity at human RARalpha expressed in HEK293 cells by luciferase reporter gene assay	[PMID: 25305688]
HL-60	EC₅₀	> 1000 1 Compound: 1	Transglutaminase activity in HL-60 cdm-1 cells Transglutaminase activity in HL-60 cdm-1 cells	[PMID: 7636843]
HL-60	EC₅₀	> 1000 1 Compound: 9 (TTNPB)	Induction of transglutaminase (TGase) activity in HL-60 cells Induction of transglutaminase (TGase) activity in HL-60 cells	[PMID: 8784454]
HL-60	ED₅₀	2.4 x 10^-9 41 Compound: TTNPB (3)	The ability to induce differentiation of human promyelocytic leukemia HL-60 cell line to mature granulocyte The ability to induce differentiation of human promyelocytic leukemia HL-60 cell line to mature granulocyte	[PMID: 2709376]
HL-60	IC₅₀	46 3 Compound: 3	In vitro cytotoxicity against HL60 cells. In vitro cytotoxicity against HL60 cells.	[PMID: 11128648]

In Vitro

TTNPB inhibits binding of [³H]tRA with IC₅₀s of 3.8 nM, 4 nM, and 4.5 nM for human RARα, β, and γ, respectively. TTNPB competes for [³H]tRA binding to CRABPI with IC₅₀s of 1800 nM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

348.48

Formula

C₂₄H₂₈O₂

CAS No.

71441-28-6

Appearance

Solid

Color

White to off-white

SMILES

O=C(O)C1=CC=C(/C=C(C2=CC=C3C(C)(C)CCC(C)(C)C3=C2)\C)C=C1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 8.33 mg/mL (23.90 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.8696 mL	14.3480 mL	28.6961 mL
5 mM	0.5739 mL	2.8696 mL	5.7392 mL
10 mM	0.2870 mL	1.4348 mL	2.8696 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: 99.85%

Select Batch:

Data Sheet (274 KB) SDS (644 KB)

COA (247 KB) HNMR (135 KB) LCMS (94 KB)

Handling Instructions (2659 KB)

References

[1]. Pignatello MA, et al. Multiple factors contribute to the toxicity of the aromatic retinoid, TTNPB (Ro 13-7410): binding affinities and disposition. Toxicol Appl Pharmacol. 1997 Feb;142(2):319-27. [Content Brief]

Kinase Assay
^[1]

Labeled and unlabeled retinoids are added to nucleosol or cytosolic fractions in ethanol so that the total amount of ethanol added is constant in all tubes and did not exceed 2% of the incubation volume. The receptor preparations are incubated with retinoids at 47°C for 4-6 hr. Sephadex PD-10 desalting columns are used to separate bound radioligand from free radioligand after equilibrium is achieved. For competitive binding assays, varying concentrations of unlabeled competing ligand are incubated with the appropriate nucleosol or cytosol in the presence of a fixed concentration of [³H]tRA (sp act. 49.3 Ci/mmol) or [³H]9-cis RA (sp. act. 24.0 Ci/mmol). Final concentrations of [³H] tRA and [³H]9-cis RA for nuclear receptor binding assays are 5nM. Final concentrations of [³H]tRA for CRABP binding assays is 30 nM. The IC₅₀s are calculated. For saturation kinetics, increasing concentrations of radiolabeled ligand ([³H]tRA sp. act. 49.3 Ci/mmol, [³H]TTNPB sp. act. 5.5 Ci/mmol) are added to the nucleosol of the appropriate receptor subtype in the presence (nonspecific binding) or absence (total binding) of a 100-fold molar excess of the corresponding unlabeled retinoid. Specific binding is defined as the total binding minus nonspecific binding. Saturation kinetics are calculated^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. Pignatello MA, et al. Multiple factors contribute to the toxicity of the aromatic retinoid, TTNPB (Ro 13-7410): binding affinities and disposition. Toxicol Appl Pharmacol. 1997 Feb;142(2):319-27. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.8696 mL	14.3480 mL	28.6961 mL	71.7401 mL
	5 mM	0.5739 mL	2.8696 mL	5.7392 mL	14.3480 mL
	10 mM	0.2870 mL	1.4348 mL	2.8696 mL	7.1740 mL
	15 mM	0.1913 mL	0.9565 mL	1.9131 mL	4.7827 mL
	20 mM	0.1435 mL	0.7174 mL	1.4348 mL	3.5870 mL

TTNPB Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

TTNPB71441-28-6Ro 13-7410 Arotinoid acid AGN191183AGN191183AGN 191183AGN-191183RAR/RXRAutophagyApoptosisRetinoic acid receptorsRetinoid X receptorsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

TTNPB (Synonyms: Ro 13-7410; Arotinoid acid; AGN191183)

Customer Review

Other Forms of TTNPB:

TTNPB Related Antibodies

5 Publications Citing Use of MCE TTNPB

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All RAR/RXR Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

TTNPB Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

TTNPB Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report